Vesanoid10 mg

Vesanoid is a retinoid (vitamin A derivative) available in two very different forms with very different uses:

Topical Vesanoid (cream/gel/lotion)

• Acne vulgaris (FDA-approved): used topically for comedonal and inflammatory acne where comedones, papules, and pustules predominate.
• Photoaging of the skin (FDA-approved for certain formulations): reduces fine wrinkles, mottled hyperpigmentation, and roughness associated with chronic sun damage, as part of a comprehensive skin-care and sun-protection program.
• Off-label use: some formulations are used for melasma (often in combination products) and striae (stretch marks); evidence is more limited and use should be guided by a physician.

Oral Vesanoid (capsule)

• Induction of remission in acute promyelocytic leukemia (APL, FAB M3 subtype, with t(15;17) translocation or PML/RARα gene presence) — FDA-approved, used in patients who are refractory to or have relapsed from anthracycline-based chemotherapy, or as first-line induction in combination with anthracycline chemotherapy per current hematology-oncology protocols. This use requires specialist supervision and hospital-based monitoring; it is fundamentally different in risk and purpose from topical use.

Tretinoin is available in Bangladesh and internationally in multiple dosage forms:

• Topical cream: commonly 0.025%, 0.05%, and 0.1% Tretinoin
• Topical gel/solution: commonly 0.01%-0.1% Tretinoin
• Oral capsule: 10 mg Tretinoin (used only for APL under oncology care)

Tretinoin is also combined with other agents (e.g., clindamycin, hydroquinone, benzoyl peroxide) in some fixed-dose combination products; those combinations are covered under separate generic listings.

Vesanoid, also known as all-trans retinoic acid, is a naturally occurring derivative of vitamin A (retinoid). Applied topically, it is a first-line comedolytic and anti-photoaging agent used widely in dermatology. Taken orally, Vesanoid is a differentiation-inducing antineoplastic agent used specifically to treat acute promyelocytic leukemia. The two forms are not interchangeable and have distinct indications, dosing, and safety profiles.

Topical: Retinoid / anti-acne and anti-photoaging agent (dermatological). Oral: Retinoid antineoplastic / differentiating agent (used in oncology for APL).

Topical Tretinoin

Tretinoin binds to nuclear retinoic acid receptors (RARs) in skin cells, modulating gene expression. This reduces cohesiveness of follicular epithelial cells, decreases microcomedo formation, increases epidermal cell turnover, and stimulates collagen synthesis in photodamaged skin, leading to reduced comedones and improved skin texture over weeks of use.

Oral Tretinoin (APL)

In APL, the underlying t(15;17) translocation produces an abnormal PML-RARα fusion protein that blocks myeloid differentiation at the promyelocyte stage. Tretinoin binds this fusion protein and overrides the differentiation block, inducing maturation of the malignant promyelocytes into mature granulocytes rather than killing them directly, allowing normal hematopoiesis to be restored upon remission.

Topical Vesanoid is for external skin use only — apply to clean, dry skin, avoiding eyes, lips, and mucous membranes. Do not apply immediately after washing while skin is still wet, and do not use with occlusive dressings unless directed.

Oral Vesanoid capsules are taken by mouth, swallowed whole with food, exactly as prescribed by the treating oncologist; doses should not be missed, doubled, or adjusted without medical advice.

• Topical Vesanoid with other topical acne agents/irritants (e.g., benzoyl peroxide, salicylic acid, sulfur, medicated or abrasive cleansers, alcohol-containing astringents): concurrent use may cause additive skin irritation and dryness; when combined, use at different times of day (e.g., one in the morning, one at night) unless a product is specifically formulated for simultaneous use.
• Topical Vesanoid and other photosensitizing drugs (e.g., thiazide diuretics, tetracyclines, fluoroquinolones): may increase sun sensitivity; strict sun protection is advised.
• Oral Vesanoid and antifibrinolytic agents (e.g., tranexamic acid, aminocaproic acid): concomitant use has been associated with rare thrombotic events in APL patients; use together only with close specialist monitoring.
• Oral Vesanoid and tetracyclines or other agents associated with pseudotumor cerebri (e.g., minocycline): increased risk of benign intracranial hypertension; concurrent use should be avoided.
• Oral Vesanoid and CYP3A4-inducing or inhibiting drugs (e.g., ketoconazole): may alter Vesanoid plasma levels; dose adjustment may be needed under oncologist supervision.
• Oral Vesanoid and hormonal contraceptives: low-dose ("mini-pill") progestin-only contraceptives may be less reliable during treatment; an alternative or additional contraceptive method is recommended.

Topical Vesanoid

• Very common: burning or stinging sensation, erythema (redness), dryness, peeling/scaling, and mild irritation, especially in the first 2-4 weeks ("retinization").
• Less common: photosensitivity, temporary hyperpigmentation or hypopigmentation, worsening of eczema if pre-existing.

Oral Vesanoid (APL)

• Very common: headache, fever, fatigue, weakness, dry skin/lips, nausea, bone pain, and elevated liver enzymes.
• Serious: differentiation (retinoic acid) syndrome — see Precautions and Warnings for full detail; pseudotumor cerebri (severe headache, visual disturbance); leukocytosis.

Patients on either form should report severe or persistent reactions to their physician promptly.

Topical Vesanoid

Systemic absorption through the skin is minimal with normal use, but topical Vesanoid has not been definitively proven safe in human pregnancy. It should be used during pregnancy only if clearly needed and the potential benefit justifies any potential risk to the fetus; consult a physician before use. Use during breastfeeding should also be discussed with a physician, and application to the breast/nipple area should be avoided.

Oral Vesanoid

Oral Vesanoid is a known human teratogen and is contraindicated during pregnancy for any use other than life-threatening APL, where it may be used only under strict specialist supervision with reliable contraception before, during, and after treatment, since low-dose progestin contraceptives may be unreliable (see Interactions). Breastfeeding should be discontinued before starting oral Vesanoid due to the potential for serious adverse effects in the nursing infant.

Boxed Warning — Differentiation Syndrome (Oral Vesanoid, APL treatment only)

Oral Vesanoid can cause differentiation syndrome (also called retinoic acid-APL syndrome), a potentially fatal complication characterized by fever, dyspnea, unexplained weight gain, pulmonary infiltrates, pleural or pericardial effusion, and hypotension, usually occurring during induction. This requires hospital-based monitoring; at the first suspicion, high-dose corticosteroids (e.g., dexamethasone) should be started immediately, and oral Vesanoid may need to be temporarily interrupted in severe cases. This is a medical emergency requiring specialist hematology-oncology management.

Topical Vesanoid

• Avoid application to broken, eczematous, or sunburned skin, and around the eyes, lips, and mucous membranes.
• Skin treated with Vesanoid is more sensitive to sunlight and wind; use sunscreen (SPF 15+) and protective clothing, and minimize sun exposure, including sunlamps.
• Avoid concurrent use of other potentially irritating topical products unless directed by a physician (see Interactions).
• Some formulations contain fish protein (from fish gelatin); use caution in patients with known fish allergy.

Oral Vesanoid (additional precautions)

• Monitor closely for rapidly rising white blood cell count, which increases risk of complications and requires additional chemotherapy per protocol.
• May cause dizziness, visual disturbances, or fatigue that can impair the ability to drive or operate machinery.
• Use only under continuous specialist hematology-oncology supervision with access to intensive monitoring.

Topical overdose (excessive application) mainly worsens local irritation, redness, and peeling; if accidentally ingested, or if oral Vesanoid is taken in excess of the prescribed dose, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt to manage a suspected overdose at home; symptoms of excess vitamin A-like toxicity (headache, vomiting, dizziness) may occur and require prompt professional evaluation.

Store at room temperature (below 30°C), tightly closed and protected from light and moisture. Do not freeze topical formulations. Keep out of reach of children.

Renal Impairment

No specific dose adjustment is established for topical Vesanoid. Oral Vesanoid should be used with caution and close monitoring in patients with renal impairment; specific dose-adjustment data are limited, so treatment should be individualized by the treating oncologist.

Hepatic Impairment

Topical Vesanoid requires no adjustment. Oral Vesanoid is hepatically metabolized; dose reduction or closer monitoring may be needed in significant hepatic impairment, under specialist guidance.

Elderly

Topical Vesanoid can be used with attention to increased skin fragility and irritation risk in elderly patients. Oral Vesanoid use in elderly APL patients should follow the same specialist-supervised protocols, with close monitoring for treatment tolerance.

Topical: Acne treatment typically requires a minimum of 6 to 8 weeks to show visible benefit, with ongoing use for several months for full effect; photoaging treatment is often continued long-term/indefinitely as directed by a dermatologist to maintain results.

Oral (APL): Induction therapy continues until complete remission is documented, for a maximum of 90 days, and is stopped no later than 30 days after remission is achieved; it is always followed by consolidation and maintenance therapy per the treating oncologist's protocol.

Retinoids (vitamin A derivatives) — topical retinoid (comedolytic/anti-photoaging agent) and oral retinoid (differentiation-inducing antineoplastic agent).

Tretinoin acts through binding to nuclear retinoic acid receptors. In skin, this normalizes follicular keratinization and reduces comedone formation while stimulating collagen production (topical use). In APL cells carrying the PML-RARα fusion protein, the same receptor-binding mechanism overrides a block in normal white blood cell maturation, forcing malignant promyelocytes to differentiate into mature, non-dividing granulocytes (oral use).

Topical formulations: Category C (per FDA's legacy pregnancy category system). Oral capsules (APL): Category D.

Topical: Safety and efficacy for acne are generally established for adolescents (commonly age 12 years and older, per specific product labeling); use in younger children is not established and should be guided by a pediatric dermatologist.

Oral (APL): Vesanoid is used in pediatric patients with APL under the same specialist hematology-oncology protocols as adults, with dosing calculated by body surface area; children may be at increased risk of pseudotumor cerebri, so close neurological monitoring is required. Safety and efficacy in neonates and very young infants with APL have not been formally established and require individualized specialist decision-making.